ES2107470T3 - Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal. - Google Patents

Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal.

Info

Publication number
ES2107470T3
ES2107470T3 ES91915528T ES91915528T ES2107470T3 ES 2107470 T3 ES2107470 T3 ES 2107470T3 ES 91915528 T ES91915528 T ES 91915528T ES 91915528 T ES91915528 T ES 91915528T ES 2107470 T3 ES2107470 T3 ES 2107470T3
Authority
ES
Spain
Prior art keywords
growth factor
glutamine
product
treatment
intestinal mucosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915528T
Other languages
English (en)
Inventor
Reinhold Kihlberg
Svante Bengt Lindgren
Lars Goran Sandberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20380209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2107470(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2107470T3 publication Critical patent/ES2107470T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN PRODUCTO QUE CONTIENE A) GLUTAMINA O UN DERIVADO O ANALOGO DE LA MISMA, B) UN ACIDO GRASO DE CADENA MEDIA O CORTA Y C) UNA HORMONA DE CRECIMIENTO O ANALOGO DE LA MISMA PARA UN USO SIMULTANEO, SEPARADO O SECUENCIAL QUE TIENE EFECTOS ANABOLICOS Y ES UTIL PARA EL TRATAMIENTO O PREVENCION DE TRASTORNOS O ENFERMEDADES DE LA MUCOSA INTESTINAL. LA HORMONA DE CRECIMIENTO ES GH, GRF, IGF-1 O IGF-2 Y PREFERENTEMENTE IGF-1. LA INVENCION SE REFIERE TAMBIEN A L USO DE GH, GRF, IGF-1 O IGF-2 PARA LA PRODUCCION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PREVENCION DE TRASTORNOS O ENFERMEDADES DE LA MUCOSA INTESTINAL.
ES91915528T 1990-08-24 1991-08-22 Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal. Expired - Lifetime ES2107470T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002732A SE9002732D0 (sv) 1990-08-24 1990-08-24 Product containing growth factor

Publications (1)

Publication Number Publication Date
ES2107470T3 true ES2107470T3 (es) 1997-12-01

Family

ID=20380209

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915528T Expired - Lifetime ES2107470T3 (es) 1990-08-24 1991-08-22 Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal.

Country Status (12)

Country Link
US (2) US5462924A (es)
EP (1) EP0547099B1 (es)
JP (1) JPH06500109A (es)
AT (1) ATE156017T1 (es)
AU (1) AU648820B2 (es)
CA (1) CA2089257A1 (es)
DE (1) DE69127087T2 (es)
DK (1) DK0547099T3 (es)
ES (1) ES2107470T3 (es)
GR (1) GR3025047T3 (es)
SE (1) SE9002732D0 (es)
WO (1) WO1992003155A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
DE69129267T2 (de) * 1990-02-13 1998-09-10 Gropep Pty. Ltd., Adelaide Methode zur behandlung intestinaler krankheiten
CA2120626C (en) * 1991-10-07 2009-10-06 Douglas Wilmore Method for enhancing gut absorption
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
JPH06510065A (ja) * 1992-06-08 1994-11-10 カイロン　コーポレーション 成長因子ｉｇｆ−ｉおよび／またはｉｇｆ−ｉｉの用法
DK25493D0 (da) * 1993-03-09 1993-03-09 Novo Nordisk As A method of treating a mammal with a biologically active compound
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5814308A (en) * 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
EP0875155A1 (en) * 1997-05-01 1998-11-04 N.V. Nutricia Peri-operative drink
WO1999040883A2 (en) 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
EP1262188A1 (en) * 2001-05-22 2002-12-04 Centre National De La Recherche Scientifique (Cnrs) Improved neuronal gene transfer
US20030099722A1 (en) * 2001-10-09 2003-05-29 Baxter Jeffrey H. Methods and compositions for providing glutamine
WO2004032653A1 (en) * 2002-10-08 2004-04-22 Abbott Laboratories Methods and compositions for providing glutamine
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
WO2009154463A2 (en) * 2008-06-20 2009-12-23 Stichting Top Institute Food And Nutrition Butyrate as a medicament to improve visceral perception in humans
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0177342A3 (en) * 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins
CA1285491C (en) * 1985-09-12 1991-07-02 Robert J. Smith Method of treating catabolic dysfunction
AU6777487A (en) * 1985-12-18 1987-07-15 Veech, R.L. Parenteral nutrition therapy with amino acids
CA1320441C (en) * 1986-01-09 1993-07-20 Douglas W. Wilmore Use of growth hormone for nitrogen retention under hypocaloric conditions
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
IL94549A (en) * 1989-06-02 1996-08-04 Brigham & Womens Hospital A pharmaceutical preparation containing glutamine
DK657689D0 (da) * 1989-12-22 1989-12-22 Novo Nordisk As Middel med biologisk virkning paa tarmslimhinden
DE69129267T2 (de) * 1990-02-13 1998-09-10 Gropep Pty. Ltd., Adelaide Methode zur behandlung intestinaler krankheiten

Also Published As

Publication number Publication date
SE9002732D0 (sv) 1990-08-24
US5462924A (en) 1995-10-31
EP0547099B1 (en) 1997-07-30
EP0547099A1 (en) 1993-06-23
DE69127087T2 (de) 1998-01-15
DK0547099T3 (da) 1998-03-09
AU648820B2 (en) 1994-05-05
CA2089257A1 (en) 1992-02-25
US5646118A (en) 1997-07-08
JPH06500109A (ja) 1994-01-06
GR3025047T3 (en) 1998-01-30
DE69127087D1 (de) 1997-09-04
AU8435991A (en) 1992-03-17
ATE156017T1 (de) 1997-08-15
WO1992003155A1 (en) 1992-03-05

Similar Documents

Publication Publication Date Title
ES2107470T3 (es) Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal.
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
HU895785D0 (en) Process for the preparation of compositions and medical preparations containing acid-resistent fibroplast growth activator for treating gastrointestinal ulcer
HUT70393A (en) Process to prepare pharmaceutical compns. for use of treatment of acne or of pseudofolliculitis barbae
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
GR1000263B (el) Μεθοδος παρασκευης αλατος της πενταμιδινης.
ATE69164T1 (de) Arzneimittel zur behandlung von uraemie.
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
DE69327314D1 (de) Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.
DE69227042D1 (de) Verfahren und zusammensetzungen zur verminderung von blutverlust
DE3687865D1 (de) Verwendung von probucol zur herstellung eines arzneimittels fuer die behandlung von herzarrhythmie.
DE3878154D1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
NO872331L (no) Farmasoeytiske preparater for behandling av bakterielle infeksjoner.
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
DE3879489D1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
PH24028A (en) The use of anipamil in the treatment of arteriosclerosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 547099

Country of ref document: ES